Innate Pharma, S.A.
Records under this name other than the patents Innate Pharma, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,675,359 | Enzymatic conjugation of antibodies Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,764,038 | Enzymatic conjugation of antibodies Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,717,803 | Enzymatic conjugation of polypeptides Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,132,799 | Screening of conjugated antibodies Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,036,010 | Recognition tags for TGase-mediated conjugation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,427,478 | Enzymatic conjugation of polypeptides Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,071,169 | Enzymatic conjugation of polypeptides Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,611,824 | Solid phase TGase-mediated conjugation of antibodies Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,434,180 | Enzymatic conjugation of polypeptides Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,119,775 | Human Anti-Kir Antibodies Term ended Term ended Oct 24, 2026 · Medium confidence | Term ended | Term ended Oct 24, 2026 | Medium confidence |